Skip to main content
Premium Trial:

Request an Annual Quote

Natera Awarded Contract to Provide Cancer Testing Services to VA

NEW YORK — Natera said on Wednesday that it has been awarded a nationwide contract from the US Department of Veterans Affairs to provide minimal residual disease assessment and treatment monitoring services with its Signatera circulating tumor DNA test.

Under the terms of the contract, which was awarded through the VA's National Precision Oncology Program, the Signatera test will be made available to the VA for serial use. According to Natera, the VA provides care to over 450,000 veterans with cancer.

Financial and other terms were not disclosed.

This summer, Austin, Texas-based Natera reported a 40 percent jump in second quarter revenues on strong sales of Signatera, particularly in its colorectal and immunotherapy monitoring indications.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.